Merck Aktie
WKN DE: A0YD8Q / ISIN: US58933Y1055
07.12.2023 14:24:06
|
Merck Stops KEYTRUDA Trial After Failing To Meet Secondary Endpoint In Metastatic Lung Cancer
(RTTNews) - Merck (MRK), known as MSD outside of the United States and Canada, Thursday announced that it will stop the Phase 3 KEYLYNK-008 trial of KEYTRUDA for the treatment of metastatic squamous non-small cell lung cancer or NSCLC. The discontinuation is due to an interim analysis 3 that compared KEYTRUDA in combination with Chemotherapy failed to demonstrate improvement in overall survival, a primary endpoint. An independent Data Monitoring Committee has recommended to stop the trial.
Further, the other dual primary endpoint, progression-free survival, was not statistically significant in the second interim analysis, despite numerical improvement compared to the control arm.
KEYTRUDA is an anti-programmed death receptor-1 therapy, based on a humanized monoclonal antibody. It was tried in combination with maintenance LYNPARZA, a PARP inhibitor

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
03.10.25 |
Freundlicher Handel: Anleger lassen Dow Jones zum Start des Freitagshandels steigen (finanzen.at) | |
02.10.25 |
Börse New York in Grün: Dow Jones zeigt sich fester (finanzen.at) | |
02.10.25 |
Minuszeichen in New York: Dow Jones notiert mittags im Minus (finanzen.at) | |
01.10.25 |
Dow Jones-Handel aktuell: Dow Jones verbucht schlussendlich Zuschläge (finanzen.at) | |
01.10.25 |
Freundlicher Handel: Dow Jones in der Gewinnzone (finanzen.at) | |
01.10.25 |
NYSE-Handel: Dow Jones auf grünem Terrain (finanzen.at) | |
30.09.25 |
Freundlicher Handel in New York: Börsianer lassen Dow Jones schlussendlich steigen (finanzen.at) | |
30.09.25 |
Pluszeichen in New York: S&P 500 schlussendlich fester (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 76,10 | 0,66% |
|